

Biosketch Pr Benoit DEPRez

Benoit Deprez received a degree of **pharmaceutical sciences** from the school of pharmacy of Lille and a **PhD in medicinal chemistry** in the Lab of André Tartar at the Institut Pasteur de Lille (1997). With André Tartar, he created the High Throughput Chemistry laboratory of the Institut Pasteur that became in 1997 the chemistry department of Cerep (now Eurofins). In 1999, after 3 years spent at Cerep as Head of Chemistry and Site Manager, he was hired by Devgen (now Syngenta), a Belgian start-up in Gent (Flanders), where he set up Drug Discovery activities using *C.elegans*. From 1995 on, he managed several collaborations between biotech or academic labs and pharmaceutical companies (GSK, Merck KGa, Sanofi, Genentech, Bioversys). He holds an MBA from Edhec Business school.

Benoit Deprez is currently Professor of Medicinal Chemistry at the Faculty of Pharmacy (U. Lille) and founder and director of U1177 based at the Institut Pasteur de Lille and the Faculty of pharmacy. His research interests primarily focus on target validation, **medicinal chemistry and pharmacokinetic**. Areas explored by U1177 are infectious diseases, metabolic and autoimmune diseases and cancer using molecular design, fragment-based approaches and KTGS coupled to cutting edge screening technologies including high throughput cell imaging. Benoit is elected member of the Académie Nationale de Pharmacie. He is director of communication of the French Medicinal Chemistry Society since 2023, member of the board of Centre Régional de Lutte contre le Cancer-Oscar Lambret, member of the Scientific Board of Directors of Institut Pasteur de Lille. In 2013, he founded APTEEUS with Terence Beghyn, a company focused on personalized drug discovery for rare metabolic diseases. Two candidate drugs discovered in his lab are currently licenced for clinical development (**alpipectir, clofoctol**).

He is author of 130 publications, H-index = 41, i10= 101, 6300 citations.